» Articles » PMID: 34278006

Pyrosequencing for Diagnosis of Multidrug and Extensively Drug-resistant Tuberculosis: A Systemic Review and Meta-analysis

Abstract

Background: Multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) pose major threats to global health. Diagnosis accuracy and delay have been the major drivers for the upsurge of M/XDR-TB. Pyrosequencing (PSQ) is a novel, real-time DNA sequencing for rapid detection of mutations associated with M/XDR-TB. We aimed to systematically synthesize the evidence on the diagnostic accuracy of PSQ for M/XDR-TB.

Methods: We conducted an electronic search of PubMed, Embase, Biosis, Web of Science, and Google Scholar up to March 2020. We used the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) tool to assess the quality of studies, the BRMA (bivariate random-effects meta-analysis) model to synthesize diagnostic accuracies, and the Rev-Man 5.4 software to perform the meta-analyses. We analyzed dichotomous data using the risk ratio (RR) with a 95% confidence interval. PROSPERO Registration ID: CRD42020200817.

Results: The analysis included seven studies, with a total sample of 3,165. At 95% confidence interval, the pooled sensitivity and specificity of PSQ were 89.7 (CI: 83.5-93.8) and 97.8 (CI: 94.9-99.1) for Isoniazid, 94.6 (CI: 90.9-96.8) and 98.5 (CI: 96.5-99.3) for Rifampicin, 87.9 (CI: 81.2-92.4) and 98.8 (CI: 97.2-99.5) for Fluoroquinolone, 83.5 (CI: 72.8-90.5) and 99.4 (CI: 98.3-99.8) for Amikacin, 79 (CI: 67-8-87) and 97.9 (CI: 95.5-99) for Capreomycin, and 69.6 (CI: 57-79.8) and 98.2 (CI: 95.9-99.2) for Kanamycin. The overall pooled sensitivity and specificity were 85.8 (CI: 76.7-91.7) and 98.5 (CI: 96.5-99.3), respectively.

Conclusion: According to the pooled data, PSQ is highly sensitive and specific for detecting M/XDR-TB, both from clinical specimens and culture isolates, and within a shorter turnaround time. We suggest a continued synthesis of the evidence on the cost-effectiveness and technical feasibilities of PSQ in low-income countries context, including sub-Saharan Africa.

Citing Articles

Urogenital Tuberculosis and Delayed Diagnosis: A Qualitative Study.

Barreto A, Lopes H, Bastos Netto J, Figueiredo A Urol Res Pract. 2024; 50(3):198-202.

PMID: 39499068 PMC: 11562921. DOI: 10.5152/tud.2024.24028.


Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis.

Schwab T, Perrig L, Goller P, Guebely De la Hoz F, Lahousse A, Minder B Lancet Infect Dis. 2024; 24(10):1162-1176.

PMID: 38795712 PMC: 11881551. DOI: 10.1016/S1473-3099(24)00263-9.


Facilitators and barriers to implementing chest radiography in tuberculosis systematic screening of clinically high-risk groups in Ethiopia: A qualitative study.

Abraham Y, Manyazewal T, Amdemariam Z, Petros H, Ayenadis F, Mekonen H SAGE Open Med. 2024; 12:20503121241233232.

PMID: 38379811 PMC: 10878208. DOI: 10.1177/20503121241233232.


Patterns of childhood tuberculosis diagnosis in Ethiopia: A multicenter cross-sectional study.

Usmael K, Manyazewal T, Mohammed H, Yimer G, Oljira L, Roba K Res Sq. 2024; .

PMID: 38234744 PMC: 10793511. DOI: 10.21203/rs.3.rs-3758745/v1.


Direct detection of drug-resistant using targeted next generation sequencing.

Murphy S, Smith C, Lapierre P, Shea J, Patel K, Halse T Front Public Health. 2023; 11:1206056.

PMID: 37457262 PMC: 10340549. DOI: 10.3389/fpubh.2023.1206056.


References
1.
Mussie K, Yimer S, Manyazewal T, Gradmann C . Exploring local realities: Perceptions and experiences of healthcare workers on the management and control of drug-resistant tuberculosis in Addis Ababa, Ethiopia. PLoS One. 2019; 14(11):e0224277. PMC: 6853283. DOI: 10.1371/journal.pone.0224277. View

2.
Lin S, Rodwell T, Victor T, Rider E, Pham L, Catanzaro A . Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol. 2014; 52(2):475-82. PMC: 3911348. DOI: 10.1128/JCM.01821-13. View

3.
Georghiou S, Seifert M, Lin S, Catanzaro D, Garfein R, Jackson R . Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis. BMC Infect Dis. 2016; 16:458. PMC: 5006534. DOI: 10.1186/s12879-016-1781-y. View

4.
Murhula Kashongwe I, Mawete F, Anshambi N, Maingowa N, Aloni M, Lukaso Losenga L . Challenge to treat pre-extensively drug-resistant tuberculosis in a low-income country: A report of 12 cases. J Clin Tuberc Other Mycobact Dis. 2020; 21:100192. PMC: 7527706. DOI: 10.1016/j.jctube.2020.100192. View

5.
Molina-Moya B, Lacoma A, Garcia-Sierra N, Blanco S, Haba L, Samper S . PyroTyping, a novel pyrosequencing-based assay for Mycobacterium tuberculosis genotyping. Sci Rep. 2017; 7(1):6777. PMC: 5533701. DOI: 10.1038/s41598-017-06760-5. View